Packer Emma, Debelle Héloïse, Bailey Harry G B, Rehman Rana Zia Ur, Yarnall Alison J, Rochester Lynn, Alcock Lisa, Del Din Silvia
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.
NPJ Parkinsons Dis. 2025 May 22;11(1):135. doi: 10.1038/s41531-025-00943-y.
To improve motor function and symptoms, people with Parkinson's (PwP) typically take dopaminergic medication. In PwP, wearable technology (WT) can provide objective insights into medication effect. This review aims to identify and explore literature which uses WT to quantify the effect of medication on motor function and symptoms in PwP (PROSPERO 2022 CRD42022310018). Nine databases were searched between January 2000-October 2024. Downs and Black quality appraisal assessed study quality. PRISMA guidelines were followed. Amongst the seventy-nine included studies, 50 different WTs were placed across 20 locations on the body, and medication effect was monitored on 13 different motor functions/symptoms. There was great heterogeneity amongst protocols, but many studies were performed in controlled environments, exploring short-term medication effects (ON vs OFF). Medication effect varied, improving certain variables, and having no effect on others. Future research should identify gold-standard protocols to explore medication effect in real-world settings, over prolonged periods.Registration and Protocol PROSPERO 2022 CRD42022310018.
为改善运动功能和症状，帕金森病患者（PwP）通常会服用多巴胺能药物。在帕金森病患者中，可穿戴技术（WT）能够提供关于药物疗效的客观见解。本综述旨在识别和探索使用可穿戴技术来量化药物对帕金森病患者运动功能和症状影响的文献（PROSPERO 2022 CRD42022310018）。在2000年1月至2024年10月期间检索了九个数据库。采用唐斯和布莱克质量评估法评估研究质量。遵循PRISMA指南。在纳入的79项研究中，50种不同的可穿戴技术放置在身体的20个部位，对13种不同的运动功能/症状进行了药物疗效监测。各方案之间存在很大异质性，但许多研究是在受控环境中进行的，探讨短期药物疗效（开与关）。药物疗效各不相同，某些变量有所改善，而对其他变量则无影响。未来的研究应确定金标准方案，以在现实环境中长时间探索药物疗效。注册及方案编号：PROSPERO 2022 CRD42022310018。
